Bioventus (BVS) Stock: Charts & Financials

Bioventus Inc.(BVS)

Medical - Devices · Durham, NC

$13.25-0.27 (-2.00%)

Delayed quote: Oct 6, 2026, 1:20 PM EDT

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Durham, NC

950 employees

www.bioventus.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Robert Claypoole

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Total Current Assets	257.53M	257.53M	249.81M	272.84M	280.90M	275.20M	249.37M	275.61M	298.69M
Cash & Cash Equivalents	29.46M	29.46M	35.85M	51.24M	42.16M	32.91M	22.80M	41.58M	43.07M
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	29.46M	29.46M	35.85M	51.24M	42.16M	32.91M	22.80M	41.58M	43.07M
Accounts Receivable	138.41M	138.41M	120.53M	128.30M	130.40M	132.37M	118.08M	127.39M	121.92M
Inventory	79.81M	79.81M	83.19M	82.24M	96.27M	96.47M	94.05M	92.47M	90.03M
Total Assets	673.35M	673.35M	650.54M	683.56M	701.59M	706.79M	691.41M	727.96M	769.49M
Property, Plant & Equipment	0.00	0.00	25.98M	27.02M	28.81M	30.74M	32.35M	33.52M	39.20M
Goodwill	7.46M	7.46M	7.46M	7.46M	7.46M	7.46M	7.46M	7.46M	7.46M
Intangible Assets	351.05M	351.05M	359.66M	368.42M	377.40M	386.95M	395.73M	404.73M	414.81M
Long-Term Investments	3.51M	3.51M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Liabilities	152.45M	152.45M	148.09M	160.38M	161.75M	185.68M	174.75M	210.40M	211.49M
Accounts Payable	20.20M	20.20M	24.05M	10.93M	26.65M	24.25M	19.20M	23.69M	16.85M
Short-Term Debt	22.89M	22.89M	18.75M	19.21M	11.25M	43.36M	37.34M	27.34M	38.57M
Total Liabilities	395.93M	395.93M	416.27M	455.11M	494.34M	505.49M	505.94M	542.35M	582.66M
Long-Term Debt	229.70M	229.70M	253.33M	278.95M	311.33M	297.88M	308.59M	308.29M	345.02M
Total Debt	263.75M	263.75M	272.08M	311.35M	322.58M	341.24M	345.93M	335.63M	383.59M
Net Debt (Cash)	234.29M	234.29M	236.23M	260.11M	280.42M	308.33M	323.13M	294.05M	340.51M
Total Shareholders' Equity	228.31M	228.31M	188.90M	184.10M	166.10M	161.24M	148.14M	147.94M	148.74M
Common Stock	84K	84K	84K	83K	83K	83K	82K	82K	81K
Retained Earnings	-298.38M	-298.38M	-331.82M	-334.93M	-349.68M	-352.84M	-360.30M	-355.08M	-354.92M
Current Ratio	1.69	1.69	1.69	1.70	1.74	1.48	1.43	1.31	1.41
Debt to Equity Ratio	1.16	1.16	1.44	1.69	1.94	2.12	2.34	2.27	2.58

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Total Current Assets

257.53M

249.81M

272.84M

280.90M

275.20M

249.37M

275.61M

298.69M

Cash & Cash Equivalents

29.46M

35.85M

51.24M

42.16M

32.91M

22.80M

41.58M

43.07M

Short-Term Investments

0.00

Cash & Short-Term Investments

29.46M

35.85M

51.24M

42.16M

32.91M

22.80M

41.58M

43.07M

Accounts Receivable

138.41M

120.53M

128.30M

130.40M

132.37M

118.08M

127.39M

121.92M

Inventory

79.81M

83.19M

82.24M

96.27M

96.47M

94.05M

92.47M

90.03M

Total Assets

673.35M

650.54M

683.56M

701.59M

706.79M

691.41M

727.96M

769.49M

Property, Plant & Equipment

0.00

25.98M

27.02M

28.81M

30.74M

32.35M

33.52M

39.20M

Goodwill

7.46M

Intangible Assets

351.05M

359.66M

368.42M

377.40M

386.95M

395.73M

404.73M

414.81M

Long-Term Investments

3.51M

0.00

Total Current Liabilities

152.45M

148.09M

160.38M

161.75M

185.68M

174.75M

210.40M

211.49M

Accounts Payable

20.20M

24.05M

10.93M

26.65M

24.25M

19.20M

23.69M

16.85M

Short-Term Debt

22.89M

18.75M

19.21M

11.25M

43.36M

37.34M

27.34M

38.57M

Total Liabilities

395.93M

416.27M

455.11M

494.34M

505.49M

505.94M

542.35M

582.66M

Long-Term Debt

229.70M

253.33M

278.95M

311.33M

297.88M

308.59M

308.29M

345.02M

Total Debt

263.75M

272.08M

311.35M

322.58M

341.24M

345.93M

335.63M

383.59M

Net Debt (Cash)

234.29M

236.23M

260.11M

280.42M

308.33M

323.13M

294.05M

340.51M

Total Shareholders' Equity

228.31M

188.90M

184.10M

166.10M

161.24M

148.14M

147.94M

148.74M

Common Stock

84K

83K

82K

81K

Retained Earnings

-298.38M

-331.82M

-334.93M

-349.68M

-352.84M

-360.30M

-355.08M

-354.92M

Current Ratio

1.69

1.70

1.74

1.48

1.43

1.31

1.41

Debt to Equity Ratio

1.16

1.44

1.69

1.94

2.12

2.34

2.27

2.58

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/06/2019	12/31/2018
Total Current Assets	272.84M	275.61M	268.00M	272.57M	263.10M	211.79M	183.03M	148.35M
Cash & Cash Equivalents	51.24M	41.58M	36.96M	30.19M	43.93M	86.84M	64.52M	42.77M
Short-Term Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	51.24M	41.58M	36.96M	30.19M	43.93M	86.84M	64.52M	42.77M
Accounts Receivable	128.30M	127.39M	122.79M	136.29M	124.96M	88.28M	85.13M	73.04M
Inventory	82.24M	92.47M	91.33M	84.77M	61.69M	29.12M	27.33M	27.40M
Total Assets	683.56M	727.96M	810.91M	1.37B	1.23B	494.47M	472.41M	442.72M
Property, Plant & Equipment	27.02M	33.52M	49.96M	44.15M	40.17M	21.84M	19.76M	4.76M
Goodwill	7.46M	7.46M	7.46M	7.46M	147.62M	49.80M	49.80M	49.80M
Intangible Assets	368.42M	404.73M	482.35M	639.85M	695.19M	191.65M	216.51M	237.03M
Long-Term Investments	0.00	0.00	0.00	2.64M	29.29M	19.38M	3.31M	2.78M
Total Current Liabilities	160.38M	210.40M	175.50M	304.02M	180.86M	122.59M	89.02M	65.43M
Accounts Payable	10.93M	23.69M	23.04M	36.70M	16.91M	4.42M	6.44M	8.21M
Short-Term Debt	19.21M	27.34M	27.85M	33.06M	18.04M	15.00M	10.00M	5.25M
Total Liabilities	455.11M	542.35M	589.79M	960.43M	692.07M	350.31M	326.79M	297.46M
Long-Term Debt	278.95M	308.29M	367.00M	385.01M	339.64M	173.38M	187.97M	189.58M
Total Debt	311.35M	335.63M	394.85M	418.07M	357.68M	188.38M	197.97M	194.83M
Net Debt (Cash)	260.11M	294.05M	357.88M	387.88M	313.75M	101.54M	133.44M	152.05M
Total Shareholders' Equity	184.10M	147.94M	173.59M	325.24M	458.92M	142.24M	142.98M	145.27M
Common Stock	83K	82K	79K	78K	75K	285.17M	285.15M	285.15M
Retained Earnings	-334.93M	-355.08M	-321.54M	-165.31M	-6.60M	-144.54M	-141.70M	-139.82M
Current Ratio	1.70	1.31	1.53	0.90	1.45	1.73	2.06	2.27
Debt to Equity Ratio	1.69	2.27	2.27	1.29	0.78	1.32	1.38	1.34

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/06/2019

12/31/2018

Total Current Assets

272.84M

275.61M

268.00M

272.57M

263.10M

211.79M

183.03M

148.35M

Cash & Cash Equivalents

51.24M

41.58M

36.96M

30.19M

43.93M

86.84M

64.52M

42.77M

Short-Term Investments

0.00

Cash & Short-Term Investments

51.24M

41.58M

36.96M

30.19M

43.93M

86.84M

64.52M

42.77M

Accounts Receivable

128.30M

127.39M

122.79M

136.29M

124.96M

88.28M

85.13M

73.04M

Inventory

82.24M

92.47M

91.33M

84.77M

61.69M

29.12M

27.33M

27.40M

Total Assets

683.56M

727.96M

810.91M

1.37B

1.23B

494.47M

472.41M

442.72M

Property, Plant & Equipment

27.02M

33.52M

49.96M

44.15M

40.17M

21.84M

19.76M

4.76M

Goodwill

7.46M

147.62M

49.80M

Intangible Assets

368.42M

404.73M

482.35M

639.85M

695.19M

191.65M

216.51M

237.03M

Long-Term Investments

0.00

2.64M

29.29M

19.38M

3.31M

2.78M

Total Current Liabilities

160.38M

210.40M

175.50M

304.02M

180.86M

122.59M

89.02M

65.43M

Accounts Payable

10.93M

23.69M

23.04M

36.70M

16.91M

4.42M

6.44M

8.21M

Short-Term Debt

19.21M

27.34M

27.85M

33.06M

18.04M

15.00M

10.00M

5.25M

Total Liabilities

455.11M

542.35M

589.79M

960.43M

692.07M

350.31M

326.79M

297.46M

Long-Term Debt

278.95M

308.29M

367.00M

385.01M

339.64M

173.38M

187.97M

189.58M

Total Debt

311.35M

335.63M

394.85M

418.07M

357.68M

188.38M

197.97M

194.83M

Net Debt (Cash)

260.11M

294.05M

357.88M

387.88M

313.75M

101.54M

133.44M

152.05M

Total Shareholders' Equity

184.10M

147.94M

173.59M

325.24M

458.92M

142.24M

142.98M

145.27M

Common Stock

83K

82K

79K

78K

75K

285.17M

285.15M

Retained Earnings

-334.93M

-355.08M

-321.54M

-165.31M

-6.60M

-144.54M

-141.70M

-139.82M

Current Ratio

1.70

1.31

1.53

0.90

1.45

1.73

2.06

2.27

Debt to Equity Ratio

1.69

2.27

1.29

0.78

1.32

1.38

1.34

Balance Sheet

Quarterly Balance Sheet (USD)

Annual Balance Sheet (USD)